Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

The Hole Story: Interatrial Shunt Companies Are—Mostly—Pushing Ahead

Michael O'Riordan

June 20, 2024

News Daily News

Cardiosave IABPs Recalled Again, This Time Due to Potential Electrical Problems: FDA

Michael O'Riordan

August 10, 2023

News Daily News

Another Recall Warns of Unheralded Shutdowns With Cardiosave IABPs

Shelley Wood

March 31, 2023

News Daily News

Second Recall in Less Than 2 Months for Cardiosave IABPs

L.A. McKeown

March 17, 2023

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

Safe to Upgrade From Pacemaker or Defibrillator to CRT

Michael O'Riordan

February 10, 2021

News Daily News

ViV TAVR Beats Redo SAVR for Short- but Not Long-term Outcomes

L.A. McKeown

July 27, 2020

News Daily News

COVID-19 Patients With Arterial Leg Thromboses Risk Amputation and Death

L.A. McKeown

July 23, 2020

News Daily News

Optimal Implantation Depth With Self-Expanding TAVR? Success May Prove Elusive

Yael L. Maxwell

December 19, 2019

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

FDA Classifies Latest HeartWare VAD Recalls as Class I

Michael O'Riordan

October 24, 2016

News Daily News

FDA Warns of Class I Recall for HeartWare VAD Batteries

Michael O'Riordan

June 29, 2016

News Daily News

BCIS-1 Published: Elective IABP Benefits High-Risk PCI Patients

Caitlin E. Cox

December 12, 2012

News Daily News

IABP Use Most Risky in ACS Patients Undergoing Urgent PCI

March 22, 2012

Advertisement

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

The Hole Story: Interatrial Shunt Companies Are—Mostly—Pushing Ahead

Cardiosave IABPs Recalled Again, This Time Due to Potential Electrical Problems: FDA

Another Recall Warns of Unheralded Shutdowns With Cardiosave IABPs

Second Recall in Less Than 2 Months for Cardiosave IABPs

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Safe to Upgrade From Pacemaker or Defibrillator to CRT

ViV TAVR Beats Redo SAVR for Short- but Not Long-term Outcomes

COVID-19 Patients With Arterial Leg Thromboses Risk Amputation and Death

Optimal Implantation Depth With Self-Expanding TAVR? Success May Prove Elusive

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

FDA Classifies Latest HeartWare VAD Recalls as Class I

FDA Warns of Class I Recall for HeartWare VAD Batteries

BCIS-1 Published: Elective IABP Benefits High-Risk PCI Patients

IABP Use Most Risky in ACS Patients Undergoing Urgent PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content